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Distribution of the c-MYC gene product in colorectal neoplasia
Aims: Recent attempts to study MYC distribution in
human samples have been confounded by a lack of
agreement in immunohistochemical staining between
antibodies targeting the N-terminus and those target-
ing the C-terminus of the MYC protein. The aim of
this study was to use a novel in-situ hybridization
(ISH) approach to detect MYC mRNA in clinically rel-
evant samples, and thereby determine the reliability
of MYC-targeting antibodies.
Methods and results: We performed immunohisto-
chemistry on human formalin-fixed paraffin embed-
ded normal colon (n = 15), hyperplastic polyp
(n = 4) and neoplastic colon samples (n = 55), using
the N-terminally directed antibody Y69, and the C-
terminally directed antibody 9E10. The MYC protein
distributions were then compared with the location
of MYC mRNA, determined by ISH. We found that
the localization of MYC mRNA correlated well with
the protein distribution determined with the N-term-
inally directed antibody Y69, and was also associ-
ated with expression of the proliferation marker
Ki67. The protein distribution determined with the
C-terminally directed antibody 9E10 was not always
associated with MYC mRNA, Y69, or Ki67, and
indeed often showed a reciprocal pattern of expres-
sion, with staining being strongest in non-proliferat-
ing cells.
Conclusions: The observed discrepancy between the
staining patterns suggests that the significance of
9E10 in immunohistochemical staining is currently
uncertain, and therefore should be interpreted with
caution.
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Introduction
Cellular MYC (c-MYC, herein referred to as MYC)
plays a role in several fundamental functions of cell
biology, including the regulation of cell growth and
proliferation, metabolism, differentiation, apoptosis,
and angiogenesis.1 Not surprisingly, deregulation of
MYC is among the most potent activators of
tumorigenesis,2 and, although MYC is the most fre-
quently amplified oncogene in human cancers,3 onco-
genic mutations in the gene itself are rare. Instead,
MYC deregulation is often a result of gene amplifica-
tion4 or mutations upstream of MYC; however, in
Burkitt’s lymphoma, chromosomal translocation is
universally the driving event.5 One of the important
consequences of MYC deregulation is aberrant
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cellular proliferation, uncontrolled by normal growth
factor signalling.
The MYC protein is a transcription factor that com-
prises an N-terminal transcription regulatory domain
(NTD), a central region containing PEST degradation
and nuclear localization signals, and a C-terminal
DNA-binding domain (CTD). The NTD engages in a
variety of protein–protein interactions with compo-
nents of the transcriptional and chromatin-remodel-
ling machinery. It contains short sequence motifs (MbI
and MbII) that are required for biological activity. The
CTD of MYC contains basic helix–loop–helix and leu-
cine zipper (bHLH-LZ) motifs that mediate interaction
with its binding partner MAX and the sequence-speci-
fic DNA binding of the MYC–MAX heterodimer.3
One of the common mechanisms of MYC deregula-
tion in cancer is amplification,6 so it is amenable to
detection by fluorescence in-situ hybridization (FISH),
and this can be a highly sensitive technique by which
the MYC copy number can be studied at cellular reso-
lution. However, there are numerous difficulties asso-
ciated with performing FISH on formalin-fixed
paraffin-embedded (FFPE) samples, e.g. the likelihood
of experimental artefacts and sample autofluores-
cence. As it is less prone to these technical problems,
antibody-based detection by immunohistochemistry
(IHC) has remained a more widely used and cost-
effective technique. IHC has been shown to provide a
good readout of MYC amplification, as a correlation
between gene amplification determined by in-situ
hybridization (ISH) and protein expression determined
by IHC has been shown in a number of cancers.7–11
Furthermore, IHC can assist in the identification of
cases in which protein overexpression has occurred
because of chromosomal rearrangement, upstream
mutation, or environmental cues.
Several antibodies against MYC have been used for
IHC and for western blotting. The ‘gold standard’ was
formerly the mouse monoclonal antibody 9E10,12
with the target epitope now known to be the C-term-
inal 10-amino acid sequence EQKLISEEDL.13 It
became clear, however, that 9E10 immunohisto-
chemical results were discrepant with other data, in
particular in high-grade carcinomas, where staining
was confined to the tumour cell cytoplasm and the
nucleus was negative, whereas it was known that
MYC in these instances exerted its function in the
nucleus.14 Such was the confusion that Williams
et al.15 erroneously posited that MYC had no role in
high-grade carcinomas of the colon.
Recently, antibodies targeting the MYC N-terminus
have been produced: N-262 (rabbit polyclonal) and
Y69 (rabbit monoclonal). Both gave excellent results
in prostate14 and lymphoid tissue16 that were largely
consistent with molecular studies. The apparent dis-
crepancy between staining patterns determined by use
of the 9E10 antibody with those determined by use of
the Y69 antibody or N-262 antibody has led to uncer-
tainty regarding the localization of MYC in normal and
tumour tissue. To determine which of the antibodies
reliably detects MYC localization in human samples,
we performed ISH for MYC mRNA, and compared this
with immunohistochemical staining with the C-term-
inally targeted 9E10 antibody and the N-terminally
targeted Y69 antibody. As MYC expression is thought
to significantly alter during colorectal cancer progres-
sion,17,18 IHC and ISH were performed on a series of
FFPE samples representing normal human colon and a
range of colonic neoplasias (n = 55).
Materials and methods
P A T I E N T S A M P L E S
FFPE samples were selected from the histopathology
archives of Charing Cross and St Mary’s Hospitals,
London, with the permission of the Imperial College
Healthcare Tissue Bank, and from University College
Hospital, London, under multicentre ethical approval
(07/Q1604/17) according to UK Home Office regula-
tions. All samples were used for IHC, and samples
represented by the numbers in square brackets were
also used for ISH. Tonsil tissue (n = 3[3]) was used to
validate our methods. Colon samples consisted of nor-
mal tissue (n = 15[8]), colorectal adenocarcinomas
(n = 24[15]), conventional adenomas (n = 20[18]),
serrated adenomas (n = 11[9]), and hyperplastic
polyps (HPPs) (n = 4[4]). Within the conventional
adenomas, there were 13 samples classified as show-
ing low-grade dysplasia (LGD), six samples showing
high-grade dysplasia (HGD), and one sample showing
both LGD and HGD. Adenomas were classified by two
expert pathologists, according to the recommenda-
tions of the Bowel Cancer Screening Programme
Pathology Group (2007) and European Guidelines.19
I M M U N O H I S T O C H E M I S T R Y
Details of immunohistochemical methods and absorp-
tion studies are given in the Supporting information.
I N - S I T U H Y B R I D I Z A T I O N
ISH for MYC mRNA expression was performed on
5-lm sections with the RNAscope 2.0 High Definition
assay (310036; Advanced Cell Diagnostics, Hayward,
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CA, USA), as previously described.20 The RNAscope
probes used were MYC (NM_002467.4, region 536–
1995, catalogue number 311761), PPIB (positive
control probe, NM_000937.4, region 139–989, cata-
logue number 313901), and dapB (negative control
probe, EF191515, region 414–862, catalogue num-
ber 310043).
Results
M Y C D I S T R I B U T I O N I N H U M A N T O N S I L
We initially examined human tonsil lymphoid tissue
(n = 3) in order to confirm that our immunohisto-
chemical staining was consistent with that previously
published. In general, immunostaining patterns in
the tonsil agreed with those of Cattoretti,16 showing
large Y69-positive cells in the light zone and the
periphery of the dark zone (founder cells), and smaller
numbers in the mantle zone (Figure S1). 9E10-posi-
tive cells followed this pattern, with additional positiv-
ity as compared with Y69. ISH for MYC mRNA,
which has not previously been performed, showed a
wider distribution of MYC expression than that
shown by MYC IHC (Figure S1), suggesting post-tran-
scriptional regulation of MYC.
M Y C D I S T R I B U T I O N I N N O R M A L A N D N E O P L A S T I C
H U M A N C O L O N
We next examined morphologically normal human
colon (n = 15) and noted that, as previously docu-
mented,21 the lower third of the crypt showed
positive staining for Y69 (Figure 1). As MYC expres-
sion is associated with proliferation, we also exam-
ined Ki67 expression, and found it to be consistent
with Y69 staining (Figure 1). The ISH for MYC
mRNA was visualized as cytoplasmic and nuclear red
dots of variable size, which were sometimes fused to
form larger foci of staining (Figure S2). We found
that MYC mRNA expression was associated with Y69
and Ki67 staining; however staining with the 9E10
antibody did not correlate with the other markers.
The nuclei of the luminal surface epithelium were
generally negative for Y69 and Ki67. Nevertheless,
we noted the presence of MYC mRNA in cells of the
surface epithelium, suggesting that a low level of
MYC expression may have been present (Figure 1). In
contrast to the other markers, 9E10 staining was
strong in the nuclei of most of the surface epithelial
lining cells, and extended to the basal portion of the
crypts (Figure 1). It is also notable that, in the lamina
propria, most of the lymphocytes were 9E10-positive
and only rarely positive for Y69 or MYC mRNA.
Because 9E10 reactivity differed from that of the
other MYC markers and was in the non-proliferating
surface cells, we confirmed the antibody specificity by
preabsorbing it with its specific epitope peptide. In
both normal colon (Figure S3A) and tumour tissue
(Figure S3B), staining was abolished by preincubation
of the antibody with 0.625–6.25 lg/ml of the block-
ing peptide, whereas 10 lg/ml of a peptide of a simi-
lar length, cerebellin, had no effect. As a further
control, we noted that 12.5 lg/ml of the blocking
peptide had no effect on Y69 staining (Figure S3C).
In conventional adenomas with LGD (n = 14),
MYC mRNA showed the greatest density in the
surface epithelium near the luminal orifice of the
H&E MYC mRNA Y69 9E10 Ki67
Figure 1. MYC expression in normal human colon. Representative haematoxylin and eosin staining, in-situ hybridization (MYC mRNA, pink)
and immunohistochemical staining with Y69 (N-terminal MYC), 9E10 (C-terminal MYC) and Ki67 antibodies (brown) in normal human
colon. The lower panels focus on the surface epithelium, which appears negative for Y69 and Ki67 expression, but strongly positive for
9E10 expression. Scale bars: 100 lm (upper panels) and 50 lm (lower panels).
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glands (Figure 2A), with expression decreasing
towards the base of the glands. The staining pattern
of Y69 was in agreement with this. We noted the
presence of adenomatous glands that showed a
highly proliferative phenotype. In these glands, the
expression of MYC mRNA and Y69 extended through
the length of the gland, and was no longer restricted
to the surface (Figure 2B). In regions of HGD (n = 7),
we found that all glands showed very high levels of
MYC mRNA and Y69 expression (Figure 2C). Strik-
ingly, in all adenoma samples, we again found that
9E10 positivity showed the reverse distribution to the
other markers, in that the extent of 9E10 positivity in
the tubules was less in HGD regions than in LGD
regions, and, indeed, the area of the tubules stained
by 9E10 appeared to be inversely related to the sever-
ity of the grading (Figure 2).
Cribriform architecture, which is characteristic of
severe dysplasia, was seen in several specimens. This
disorganization is reflected in the location of the MYC
mRNA and of Y69 immunostaining (Figure S4). In
the instances studied, the nuclei were negative for
9E10, again in contrast to the expression of the other
markers.
Serrated lesions have a distinct pathway of progres-
sion, and we have recently shown that serrated ade-
nomas retain a stem cell hierarchy, whereas their
conventional counterparts do not.20 We therefore
H&E MYC mRNA Y69 9E10 Ki67
H&E MYC mRNA Y69 9E10 Ki67
H&E MYC mRNA Y69 9E10 Ki67
A
B
C
Figure 2. MYC expression in conventional adenomas. A, Representative haematoxylin and eosin (H&E) staining, in-situ hybridization (MYC
mRNA, pink) and immunohistochemical staining with Y69 (N-terminal MYC), 9E10 (C-terminal MYC) and Ki67 antibodies (brown) in ade-
noma with low-grade dysplasia. A ‘reverse gradient’ of MYC mRNA and Y69 expression, with highest expression at the luminal surface, is
apparent. Scale bars: 200 lm. B, Representative H&E staining, in-situ hybridization (MYC mRNA, pink) and immunohistochemical staining
with Y69 (N-terminal MYC), 9E10 (C-terminal MYC) and Ki67 antibodies (brown) in adenoma, focusing on a gland with a highly prolifera-
tive phenotype. Again, a reverse gradient is apparent, although, in the proliferative gland, the MYC mRNA, Y69 and Ki67 expression can
be seen extending to the base of the crypt, in contrast to the surrounding glands and normal crypts. Scale bars: 500 lm (upper panels) and
200 lm (lower panels). C, Representative H&E staining, in-situ hybridization (MYC mRNA, pink) and immunohistochemical staining with
Y69 (N-terminal MYC), 9E10 (C-terminal MYC) and Ki67 antibodies (brown) in high-grade dysplasia. Extensive positivity for MYC mRNA,
Y69 and Ki67 is apparent, whereas 9E10 staining is remarkably weak. Scale bars: 200 lm.
© 2016 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 69, 222–229.
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examined MYC expression in traditional serrated ade-
nomas (TSAs) (n = 3), sessile serrated adenomas
(SSAs)/sessile serrated polyps (SSPs) (n = 6), and
HPPs (n = 4).
TSAs showed irregular foci of growth perpendicular
to the line of the crypt (‘ectopic crypts’). In the bases of
these ectopic foci, positive staining for MYC mRNA,
Y69 and Ki67 was seen (Figure 3). 9E10 staining was
moderate throughout the lesion, but the marked high
intensity of expression of the other markers at the
bases of ectopic crypts was not seen (Figure 3).
We next examined the MYC distribution in HPPs,
which are traditionally regarded as benign serrated
lesions. In HPPs, the distribution of the markers was
similar to that seen in the normal colon, with Ki67,
Y69 and MYC mRNA concentrated in the basal
portions of the crypts (Figure 4). As previously
reported,20,22 this zone of proliferation is more exten-
sive than that of normal colon, but does not extend
to the surface epithelium. However, in contrast to the
other markers, we observed high levels of 9E10 stain-
ing in the surface epithelium (Figure 4). The staining
observed in SSA/SSPs was generally similar to that
described for HPPs.
In invasive carcinomas, the expression of MYC
protein (by Y69 staining) and MYC mRNA was much
greater than in most of the adenomas, but similar to
that in those with the most severe dysplasia
(Figure 5A,B). We noted a high level of heterogeneity
in invasive glands, some of which contained regions
of low MYC expression and, indeed, negative areas
(Figure 5A). As previously reported,15 9E10 nuclear
staining was often absent in carcinomas. However,
there were frequent scattered stretches of neoplastic
H&E MYC mRNA Y69 9E10 Ki67
Figure 3. MYC expression in traditional serrated adenomas. Representative haematoxylin and eosin staining, in-situ hybridization (MYC
mRNA, pink) and immunohistochemical staining with Y69 (N-terminal MYC), 9E10 (C-terminal MYC) and Ki67 antibodies (brown) in a tra-
ditional serrated adenoma. Strong positivity for MYC mRNA, Y69 and Ki67 is apparent in ectopic crypt foci. Scale bars: 200 lm (upper pan-
els) and 100 lm (lower panels).
H&E MYC mRNA Y69 9E10 Ki67
Figure 4. MYC expression in hyperplastic polyps. Representative haematoxylin and eosin staining, in-situ hybridization (MYC mRNA, pink)
and immunohistochemical staining with Y69 (N-terminal MYC), 9E10 (C-terminal MYC) and Ki67 antibodies (brown) in a hyperplastic
polyp. The lower panels focus on the surface epithelium, which appears negative for Y69 and Ki67 expression, but strongly positive for
9E10 expression. Scale bars: 500 lm (upper panels) and 100 lm (lower panels).
© 2016 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 69, 222–229.
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epithelium that were positive for 9E10, but negative
for Y69 and Ki67, and with low levels of MYC
mRNA. We noted examples of such areas adjacent to
focal regions of proliferating cells; the reciprocal rela-
tionship between Y69 and 9E10 staining was partic-
ularly clear here (Figure 5A).
Rubio23 described flattened areas in the advancing
edge of colonic adenocarcinomas that were negative
for Ki67. Our results confirm this (Figure 5B), and
we further note that Y69 immunopositivity and MYC
mRNA were also absent. However, these nuclei were
positive for 9E10. Additional foci of stromal invasion
could be found that were not flattened, and many of
these showed the same distribution of markers.
Discussion
MYC is accepted as one of the most potent drivers of
tumorigenesis; however, recent attempts to examine
its expression have been confounded by inconsisten-
cies in antibody immunoreactivity. We have
attempted to resolve this issue by comparing detec-
tion of MYC by the use of conventional IHC with a
novel ISH approach that specifically detects MYC
mRNA in FFPE tissue sections.
We have shown that MYC mRNA, MYC protein (by
Y69 immunostaining) and Ki67 are found in the lower
third of normal human colonic crypts. However, we
have found that positivity of the C-terminally targeted
antibody 9E10 does not always correlate with these
markers. In fact, the staining often shows a striking
inverse relationship, with the non-proliferating surface
epithelium of normal crypts staining positively for
9E10. There are very low, but detectable, levels of MYC
mRNA in the surface epithelium, and MYC expression
has been shown in non-proliferating cells.24–26 There-
fore, 9E10 could be detecting an alternative conforma-
tion of MYC, which may not play a role in driving
H&E MYC mRNA Y69 9E10 Ki67
H&E MYC mRNA Y69 9E10 Ki67
A
B
Figure 5. MYC expression in invasive carcinoma. A, Representative haematoxylin and eosin (H&E) staining, in-situ hybridization (MYC
mRNA, pink) and immunohistochemical staining with Y69 (N-terminal MYC), 9E10 (C-terminal MYC) and Ki67 antibodies (brown) in a
region of invasive carcinoma. The lower panels highlight the reciprocal relationship between the expression of MYC mRNA, Y69, and Ki67,
and the staining of the 9E10 antibody. B, Representative H&E staining, in-situ hybridization (MYC mRNA, pink) and immunohistochemical
staining with Y69 (N-terminal MYC), 9E10 (C-terminal MYC) and Ki67 antibodies (brown) in a region of invasive carcinoma. The lower
panels focus on an invasive gland showing flattened non-proliferative cells at the invasive edge, which are notably Y69-negative and 9E10-
positive. Scale bars: 200 lm (upper panels) and 50 lm (lower panels).
© 2016 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 69, 222–229.
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proliferation. For example, there is a form of MYC
(‘MYC-S’) that lacks the proximal 100 N-terminal
amino acids,27 containing the region in which the Y69
epitope is located. However MYC-S has been shown to
retain the ability to stimulate proliferation,28 so it prob-
ably cannot explain the 9E10 staining in the non-pro-
liferating cells of the surface epithelium. Alternatively,
although our absorption studies have shown the stain-
ing to be specific to the epitope, it is possible that 9E10
may cross-react with another protein.
As MYC plays a role at some stage in the develop-
ment of most colorectal carcinomas,18 we studied the
spatial distribution of MYC protein and MYC mRNA
in adenomas. We concluded that the distribution of
these markers agreed remarkably well with the tradi-
tional morphological classification. Our results sug-
gest strong expression of MYC mRNA and Y69 in
high-grade lesions and in invasive carcinomas. We
confirm the results of a previous report23 that
described flattened Ki67-negative cells at the invading
edge of colorectal carcinomas. We found this feature
only as a focal occurrence, but confirm that, in such
areas, both MYC expression and Ki67 are down-regu-
lated. Such changes in cell shape and gene expression
could be indicative of an epithelial-to-mesenchymal
transition, which is known to be a feature of the
invasive phenotype.29
Cribriform architecture in adenomatous glands indi-
cates HGD. Here, the highly irregular localization of
MYC mRNA suggests that there is disorientation of cell
growth, a marker of malignancy. The intense expres-
sion of MYC in the carcinomas is in line with the
known overproduction of MYC mRNA and MYC pro-
tein described in these processes.18 As in all areas of
high-grade malignancy, 9E10 staining was notably
absent. The absence of 9E10 staining in high-grade
neoplastic cells has been previously reported.14,15 Sug-
gested explanations include deletion of parts of the MYC
molecule, the presence of unknown isomers, and inter-
ference with 9E10 binding by other nuclear proteins.
Another explanation for the apparent reciprocal
relationship between Y69 and 9E10 immunoreactiv-
ity relates to the physical nature of the MYC mole-
cule. MYC is one of a group of so-called intrinsically
disordered proteins,30,31 and can adopt conformations
ranging from collapsed to fully extended. Both the
unstructured NTD and the largely unstructured
bHLH-LZ domain at the C-terminus change their con-
figurations when bound to certain proteins. It has
been shown that monoclonal antibody binding is
affected by structural changes in proteins,32,33 so it is
possible that structural changes in MYC can affect
the binding of anti-MYC antibodies.
In this study, we have used a comparison of ISH
and IHC to raise key questions concerning the speci-
ficity of the MYC-targeting antibody 9E10. Our
results suggest that 9E10 does not recognize MYC in
its classic proliferation-associated form; however, this
does not exclude the possibility that it binds to a dif-
ferent conformation of MYC. As 9E10 positivity
occurs when proliferation appears to be inhibited, it
follows that MYC may adopt different conformations
to promote contradictory cellular states, a possibility
that is suggested by experimental inhibitors of the
HUWE1 ubiquitin ligase.34 Further investigation into
the specificity of MYC-targeting antibodies is needed,
and care should be taken when drawing conclusions
from immunohistochemical staining for MYC, partic-
ularly with 9E10.
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Figure S1. MYC expression in human tonsil.
Figure S2. MYC mRNA ISH in normal human
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Figure S3. Absorption studies using the 9E10
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Figure S4. MYC expression in high-grade dysplasia.
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